
Sign up to save your podcasts
Or


The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).
By BMJ Group4.8
44 ratings
The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).

1,086 Listeners

863 Listeners

159 Listeners

2,113 Listeners

1,996 Listeners

40 Listeners

49 Listeners

93 Listeners

9 Listeners

7 Listeners

4 Listeners

2 Listeners

3 Listeners

10 Listeners

41 Listeners

14 Listeners

1 Listeners

53 Listeners

0 Listeners

6 Listeners

15 Listeners

17 Listeners

3 Listeners

26 Listeners

1,101 Listeners

23 Listeners

8 Listeners

21 Listeners

170 Listeners

3,858 Listeners

2,131 Listeners

907 Listeners

6 Listeners

0 Listeners